AntibioBoNTA
What it found
No result yet.
What was tested
Treatment tested
- Onabotulinumtoxina
Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
Compared with
- Onabotulinumtoxina
Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
What it measured
Main measures
Rate of patients with symptomatic UTI occurring within the 6 weeks following intra-vesical BoNTA injections.
Other measures (1)
Safety:
Safety
Who could take part
MS (type not specified)
Inclusion: -Female and male over 18 years-old Exclusion: - Having already participated to the study
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To demonstrate the non-inferiority of “antibiotic saving strategy” compared to
Loading reviews and guidelines…
Related trials
- ICE Trial
Phase 4 · Ongoing (inferred)
Still running
- A Study to Investigate Arbaclofen ER Tablets for the Trea…
Phase 3 · Not yet recruiting
Still running
- Silodosin for Urinary Symptoms in Female Patients With Mu…
Phase 4 · Recruiting
Still running
- Cannabis (THC vs. CBD) in Multiple Sclerosis
Phase 2 · Recruiting
Still running
- ICE
Phase 4 · Recruiting
Still running
- ALPHA-SEP
Not a drug-phase study · Status unknown
No result found
History
Started
Mar 2022
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error